WTA to require genetic sex testing for all players
En resumen
- The WTA will implement a new eligibility policy in 2026, requiring all players to undergo genetic sex testing for the SRY gene to compete on the Tour.
- A negative result is needed, with positive tests leading to further medical assessment.
- This updates a 2024 policy on testosterone levels.
Resumen generado por IA
Por qué importa
The WTA's updated women's eligibility policy, effective 2026, will mandate genetic sex testing for all players, requiring a negative SRY gene test to compete. This replaces a 2024 policy based on testosterone levels.
The Women's Tennis Association (WTA) is to require all players to undergo genetic sex testing in order to compete on the WTA Tour.
In the latest edition of its women's eligibility policy, which will come into effect on Tuesday, players will be required to provide a cheek swab, blood or saliva sample to test for the presence of the SRY gene which is part of the Y chromosome and causes male characteristics to develop.
Players will be tested just once in their lifetime and only a negative result, showing no presence of the gene, will permit them to compete on the Tour.
If they test positive, players will face further medical assessment before being allowed to play.
The new policy also requires players to sign a document that states they could face disciplinary action if they refuse testing.
The WTA's previous policy, last updated in 2024, allowed transgender women to compete on the Tour if they had lowered their testosterone levels to below 2.5 nmol/L continuously for the previous two years.
There are no known transgender women currently playing on the WTA Tour.
"The WTA's women's eligibility policy is designed to promote equal athletic opportunities in women's professional tennis and maintain fair competition for all players participating in WTA tournaments," the governing body said.
"Since first being introduced in 1975, the eligibility policy has undergone periodic review in light of developments across international sport.
"Following the most recent review, which included consultation with WTA members and evolving standards across women's sport, the WTA board approved an updated WTA women's eligibility policy beginning in 2026 based on biological sex."
It added: "The WTA recognises that this is a sensitive and complex issue and is committed to treating all players with dignity and implementing the policy in a respectful and thoughtful way."
The policy change comes a year after World Athletics announced new regulations - brought into effect in September 2025 - requiring athletes wanting to compete in the female category for world ranking competitions to take a one-time gene test.
Qué observar
Perspectiva de IA — posibilidades, no hechos
Players will undergo genetic sex testing for the SRY gene before competing on the WTA Tour.
Muy probable · En meses
Players refusing testing could face disciplinary action.
Muy probable · En meses
Preguntas abiertas
- How will the policy be enforced globally?
- What specific medical assessments will positive testers face?
- How will the policy impact player participation?







